Skip to main content
Signal8

Liminatus Pharma, Inc. (LIMNW)

Liminatus Pharma, Inc., situated in La Palma, California, is an immuno-oncology firm actively engaged in clinical trials, dedicated to pioneering innovative treatments for various cancers.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Liminatus Pharma, Inc. Warrants logo

Liminatus Pharma, Inc. Warrants

NASDAQ:LIMNWSub-class of LIMNHealthcare
+13.96%$0.0400
Mkt Cap$54K
EV$1.19M
Float-
O/S1.34M
VOL251 sh
$ Vol$10
RVOL1.31×
Inst Own-
SI0.1%
Net Cash/Sh-$0.82
Dilution
Liminatus Pharma, Inc. Warrants logoNASDAQ:LIMNW$0.0400+13.96%
Financials Summary
Revenue$0
Net Income-$10.21M
Total Assets$513K
Free Cash Flow-$9.98M
Debt & Equity
Total Debt$1.44M
Total Equity-$9.81M
Shares Outstanding
Short Interest

No short interest data available.

Split History

No splits on record

Nothing in LIMNW's public trading history: no forward or reverse split has affected the share count.

Balance Sheet Details
Assets$513K
Liabilities$10.33M
Accounts Receivable$0
Accounts Payable$582K
Inventory$0
PP&E (Net)$12K
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue$0$0$0$0$0
YoY Growth-----
Cost of Revenue$0$0$0$0$0
Gross Profit$0$0$0$0$0
Gross Margin-----
Research and Development$0$2.69M$3.76M$1.85M$3.8M
Selling, General, and Administrative$2.97M$645K$1.06M$856K$197K
Other$0-$424K-$2.23M$0-$1.46M
Total Operating Expenses$2.97M$2.91M$2.59M$2.71M$2.53M
Operating Income (EBIT)-$2.97M-$2.91M-$2.59M-$2.71M-$2.53M
Operating Margin-----
Interest Expense$216K$138K$175K$219K$0
Interest Income$77K$138K$10K$0$17K
Other Income (Expense)-$7.24M$21K$1.39M-$219K$6.9M
Income Before Tax (EBT)-$10.21M-$2.89M-$1.19M-$2.93M$4.37M
Income Tax Expense$0$19K$34K$0$0
Net Income-$10.21M-$2.9M-$1.23M-$2.93M$4.37M
Net Income Margin-----
Supplementary Data
EPS-21.50-20.00-7.50-4.126.50
Diluted EPS-21.50-20.00-7.50-4.126.50
Weighted Average OS475,071143,832160,251688,565690,000
EBITDA-$9.99M-$2.75M-$1.09M-$2.71M$4.37M
EBITDA Margin-----
Balance Sheet
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Assets
Current Assets
Cash and Cash Equivalents$338K$805K$434K$5.05M$336K
Short-Term Investments$0$0$0$0$0
Cash and Short-Term Investments$338K$805K$434K$5.05M$336K
Accounts Receivable$0$6K$945K$100K$1K
Inventory$0$0$0$0$0
Other Current Assets$163K$2K-$1.17M-$6.47M$84K
Total Current Assets$501K$813K$211K$361K$422K
Long-Term Assets
Property, Plant & Equipment Net$12K$0$1K$1K$0
Goodwill$0$0$0$0$0
Intangible Assets$0$0$0$0$0
Long-Term Investments$0$2.02M$4.29M$15.13M$276.02M
Deferred Tax Assets$0$0$0$0$0
Other Long-Term Assets$0$0-$1K-$1K$0
Total Long-Term Assets$12K$2.02M$4.29M$15.13M$276.02M
Other Assets$0$0$0$0$0
Total Assets$513K$2.83M$4.5M$15.49M$276.44M
Liabilities
Current Liabilities
Accounts Payable$582K$1.48M$933K$508K$419K
Short-Term Debt$1.44M$5.12M$16.05M$16.5M$90K
Current Income Tax Payable$0$0$0$0$0
Current Unearned Revenue$0$0$0$0$0
Other Current Liabilities$0$2.08M-$12.88M-$14.06M$871K
Total Current Liabilities$10.3M$8.68M$5.16M$3.59M$1.38M
Long-Term Liabilities
Long-Term Debt$0$0$0$0$0
Long-Term Unearned Revenue$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0
Other Long-Term Liabilities$29K$10.02M$10.04M$10.6M$20.19M
Total Long-Term Liabilities$29K$10.02M$10.04M$10.6M$20.19M
Other Liabilities$0$0$0$0$0
Total Liabilities$10.33M$18.7M$15.19M$14.19M$21.57M
Stockholders' Equity
Preferred Stock$0$0$0$0$0
Common Stock$3K$1.76M$4.05M$15.13M$276M
Retained Earnings-$38.87M-$17.52M-$14.88M-$13.97M-$21.13M
Comprehensive Income & Other$0-$161K$0$0$0
Other Stockholders' Equity$29.05M-$109K$140K$140K$0
Total Equity-$9.81M-$15.87M-$10.69M$1.29M$254.87M
Minority Interest$0$0$0$0$0
Total Liabilities and Equity$513K$2.83M$4.5M$15.49M$276.44M
Supplementary Data
Total Debt$1.44M$5.12M$16.05M$16.5M$90K
Net Debt$1.1M$4.32M$15.62M$11.45M-$246K
Cash Flow Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Operating Activities
Net Income-$10.21M-$2.9M-$4.98M-$2.93M$4.37M
Depreciation & Amortization$2K$0$0$1K$0
Deferred Income Tax$0$0$0$0$0
Stock-Based Compensation$0$0$0$0$0
Changes in Working Capital:
  Accounts Receivable-$3.43M$48K$0$0$0
  Inventory$0$0$0$0$0
  Accounts Payable-$4.04M$0$425K$89K$0
  Other Working Capital$478K-$93K$1.21M$1.07M$1.32M
Total Working Capital Change-$6.98M-$45K$1.64M$1.16M$1.32M
Other Non-Cash Items$7.23M-$158K$0$899K-$6.9M
Net Cash from Operating-$9.96M-$3.11M-$3.35M-$869K-$1.22M
Investing Activities
Capital Expenditures-$13K$0$0$0$0
Acquisitions$4.44M$0$0$0$0
Purchases of Investments$0-$189K-$121K$0-$276M
Sales of Investments$0$2.16M$0$0$0
Other Investing Activities-$5.22M$0-$698K$0$0
Net Cash from Investing-$788K$1.97M-$819K$0-$276M
Financing Activities
Debt Repaid-----
Common Stock Issuance$10.56M$0$0$4.2M$283.07M
Common Stock Repurchases$0-$1.8M-$10.66M-$700K$0
Dividends Paid$0$0$0$0$0
Other Financing Activities-$2.56M$0$10.66M$0-$5.52M
Net Cash from Financing$11.03M$1.05M-$450K$5.92M$277.55M
Forex Effect$0$739K$0$0$0
Net Change in Cash$281K$648K-$4.61M$5.05M$336K
Supplementary Data
Operating Cash Flow-$9.96M-$3.11M-$3.35M-$869K-$1.22M
Capital Expenditure-$13K$0$0$0$0
Free Cash Flow-$9.98M-$3.11M-$3.35M-$869K-$1.22M
Cash at Beginning$56K$156K$5.05M$336K$0
Cash at End$338K$805K$434K$5.38M$336K